IPO registrations (S-1, F-1) · Registrants
Strongbridge Biopharma plc
- SEC CIK
- 1634432 · filings on EDGAR ↗
- Former names
- Cortendo AB (2015–2015)
- Registration
- Form F-1, first filed 2015-08-28, last 2015-10-14; 1 initial registration, 5 amendments
- Outcome
- Final prospectus filed 2015-10-16; declared effective 2015-10-15
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L2
- Business address
- 900 NORTHBROOK DRIVE, SUITE 200, Trevose, PA 19053
- EIN
- 98-1130690
- EDGAR entity type
- operating
- Insiders and CEO pay
- Strongbridge Biopharma plc on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2015-10-16, an initial public offering)
- Shares sold
- 2,500,000
- Gross proceeds
- $25,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SBBP
- Lead underwriters
- Stifel
- Syndicate
- JMP Securities (500,000); Roth Capital Partners (312,500); Arctic Securities; Arctic Securities AS (125,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Strongbridge Biopharma plc EXACT (CIK (EXACT))
- Lobbying client: STRONGBRIDGE BIOPHARMA PLC Fuzzy (name and state)
- Lobbying client: STRONGBRIDGE BIOPHARMA, PLC Fuzzy (name and state)
- SEC filer: Strongbridge Biopharma plc EXACT (CIK (EXACT))
- Person page: Jeffrey W Sherman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-08-28 | F-1 | F-1 (foreign registration) | Cortendo AB | 0001047469-15-007060 ↗ |
| 2015-09-09 | F-1/A | F-1/A (amendment) | Strongbridge Biopharma plc | 0001047469-15-007207 ↗ |
| 2015-09-21 | F-1/A | F-1/A (amendment) | Strongbridge Biopharma plc | 0001047469-15-007440 ↗ |
| 2015-09-25 | F-1/A | F-1/A (amendment) | Strongbridge Biopharma plc | 0001047469-15-007543 ↗ |
| 2015-09-30 | F-1/A | F-1/A (amendment) | Strongbridge Biopharma plc | 0001047469-15-007618 ↗ |
| 2015-10-14 | F-1/A | F-1/A (amendment) | Strongbridge Biopharma plc | 0001047469-15-007854 ↗ |
| 2015-10-15 | EFFECT | EFFECT (declared effective) | Strongbridge Biopharma plc | 9999999995-15-002760 ↗ |
| 2015-10-16 | 424B4 | 424B4 (final prospectus) | Strongbridge Biopharma plc | 0001047469-15-007903 ↗ |
| 2017-02-02 | EFFECT | EFFECT (declared effective) | Strongbridge Biopharma plc | 9999999995-17-000275 ↗ |
| 2017-05-08 | EFFECT | EFFECT (declared effective) | Strongbridge Biopharma plc | 9999999995-17-001223 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-10-14 | F-1/A | registration statement | $10.00 | 2,500,000 | $25,000,000 | Nasdaq SBBP | 4 | primary document; price sentence, shares headline, proceeds computed, cover names 4 | document ↗ | |
| 2015-10-16 | 424B4 | final prospectus | $10.00 | 2,500,000 | $25,000,000 | Nasdaq SBBP | 5 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cohen Fredric J. | Officer | Chief Medical Officer | 12 | 2018–2021 | |
| DAVIS A BRIAN | Officer | Chief Financial Officer | 4 | 2018–2019 | |
| JOHNSON JOHN | Director; Director,Officer | Chief Executive Officer; Executive Chairman | 12 | 2018–2021 | |
| Kollender Richard S | Director; Officer | Chief Operating Officer; President and CFO | 11 | 2018–2021 | |
| Kong Garheng | Director | 9 | 2018–2021 | ||
| LONG STEPHEN J | Officer | Chief Legal Officer | 9 | 2018–2021 | |
| Pauls Matthew | Director,Officer | President & CEO | 4 | 2018–2019 | |
| SHERMAN JEFFREY W | Director | 9 | 2018–2021 | person page Fuzzy | |
| Steen Marten | Director | 9 | 2018–2021 | ||
| Steineger Hilde H | Director | 9 | 2018–2021 | ||
| BARRETT M JAMES | TenPercentOwner | 1 | 2018 | ||
| BARRIS PETER J | TenPercentOwner | 1 | 2018 | ||
| BASKETT FOREST | TenPercentOwner | 1 | 2018 | ||
| CAXTON CORP | TenPercentOwner | 10 | 2018–2022 | ||
| CDK ASSOCIATES, L.L.C. | TenPercentOwner | 10 | 2018–2022 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 1 | 2018 | ||
| Growth Equity Opportunities Fund III, LLC | TenPercentOwner | 1 | 2018 | ||
| KERINS PATRICK J | TenPercentOwner | 1 | 2018 | ||
| Kovner Bruce | TenPercentOwner | 10 | 2018–2022 | ||
| MOTT DAVID M | TenPercentOwner | 1 | 2018 | ||
| NEA 14 GP, LTD | TenPercentOwner | 1 | 2018 | ||
| NEA Partners 14, L.P. | TenPercentOwner | 1 | 2018 | ||
| New Enterprise Associates 14, L.P. | TenPercentOwner | 1 | 2018 | ||
| SANDELL SCOTT D | TenPercentOwner | 1 | 2018 | ||
| Sonsini Peter W. | TenPercentOwner | 1 | 2018 | ||
| Viswanathan Ravi | TenPercentOwner | 1 | 2018 | ||
| Wilhoit Scott L. | Officer | Chief Commercial Officer | 7 | 2019–2021 | |
| GILL DAVID N | Director | 9 | 2019–2021 | ||
| Lutz Robert Matthew | Officer | Chief Financial Officer | 4 | 2019–2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-12-30 | Strongbridge Biopharma plc | Pharmaceuticals | $35,000,000 | $35,000,000 | 23 | 1 |
| 2015-09-14 | Strongbridge Biopharma plc | Pharmaceuticals | $126,000,000 | $126,000,000 | 46 | 1 |
| 2015-07-17 | Cortendo AB | Pharmaceuticals | $33,224,981 | $33,224,981 | 25 | 1 |
| 2015-02-25 | Cortendo AB | Pharmaceuticals | $26,397,676 | $26,397,676 | 5 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | STRONGBRIDGE BIOPHARMA PLC | PA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Strongbridge Biopharma plc | PA | Form D private offerings | CIK (EXACT) |
| Lobbying client | STRONGBRIDGE BIOPHARMA PLC | PA | Federal lobbying (LDA) | name and state |
| Lobbying client | STRONGBRIDGE BIOPHARMA, PLC | PA | Federal lobbying (LDA) | name and state |
| SEC filer | Strongbridge Biopharma plc | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Jeffrey W Sherman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, PA first:
- COLLAGENEX PHARMACEUTICALS INC PA
- ORAPHARMA INC PA
- VICURON PHARMACEUTICALS INC PA
- INOVIO PHARMACEUTICALS, INC. PA
- ADOLOR CORP PA
- PROTARGA INC PA
- Traws Pharma, Inc. PA
- MADRIGAL PHARMACEUTICALS, INC. PA
- Vitae Pharmaceuticals, Inc PA
- PhaseBio Pharmaceuticals Inc PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health